



to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10797257.str



chain nodes :

7 8 9 10 11 12 13

ring nodes :

1 2 3 4 5 6

chain bonds :

4-7 5-12 6-8 8-9 9-10 10-11 12-13

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 6-8 8-9 12-13

exact bonds :

5-12 9-10 10-11

isolated ring systems :

containing 1 :

G1:C,O,S

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
 11:CLASS 12:CLASS 13:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,O,S

<09/07/2005>

Habte

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 08:50:34 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 19 TO ITERATE

100.0% PROCESSED 19 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 119 TO 641  
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 08:50:42 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 262 TO ITERATE

100.0% PROCESSED 262 ITERATIONS 18 ANSWERS  
SEARCH TIME: 00.00.01

L3 18 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.33	161.54

FILE 'CAPLUS' ENTERED AT 08:50:49 ON 07 SEP 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Sep 2005 VOL 143 ISS 11  
FILE LAST UPDATED: 6 Sep 2005 (20050906/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 2 L3

<09/07/2005>

Habte

=> d ibib abs hitstr tot

Own  
work

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:

2004:817887 CAPLUS

DOCUMENT NUMBER:

141:314052

TITLE:

Preparation of prostaglandin analogs as EP4 receptor

INVENTOR(S):

Billot, Xavier; Colucci, John; Han, Yongxin; Wilson,

PATENT ASSIGNEE(S):

Marie-Claire; Young, Robert N.

SOURCE:

Merck Frost Canada &amp; Co., Can.

DOCUMENT TYPE:

PCT Int. Appl., 69 pp.

LANGUAGE:

CODEN: PIXXD2

FAMILY ACC. NUM. COUNT:

Patent

PATENT INFORMATION:

English

FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004085430	A1	20041007	WO 2004-CA470	20040326
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, EE, EG, ES, FI, GB, GD, GE, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
US 2004198701	A1	20041007	US 2004-787257	20040310
WO 2004085431	A1	20041007	WO 2004-CA471	20040326
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, EE, EG, ES, FI, GB, GD, GE, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

PRIORITY APPL. INFO.:

US 2003-457700P

P 20030326


OTHER SOURCE(S):

MARPAT 141:314052

G1

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

(Continued)



AB Prostaglandin analogs of formula 1 [Q = alkylene, alkylarylene, alkylcycloalkylene, etc.; X, Y = CH<sub>2</sub>, O, (substituted) NH, S; U = H, alkyl, absent; V = OH, oxo; R<sub>1</sub> = hydroxyalkyl, cyanoalkyl, carboxy, heterocyclylalkyl, etc.; R<sub>2</sub> = alkyl, aryl, heteroaryl, etc.; R<sub>3</sub>, R<sub>4</sub> = H, halo, alkyl; R<sub>3</sub>R<sub>4</sub> = alkylene, etc.; Z = triple bond, O, S, CH=CH, etc.; n = 0-4] are prepared as potent selective agonists of the EP4 subtype of prostaglandin E<sub>2</sub> receptors, and can be used in a formulation for the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compds. of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts. Thus, II was prepared in several steps from (R)-pipercolonic acid.


IT 768399-98-OP

RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (Preparation of prostaglandin analogs as EP4 receptor agonists for the treatment of glaucoma)

RN 768399-98-0 CAPLUS

CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]dihydro-2-oxo-, 1-methylethyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



IT 768399-99-1P 768400-11-9P 768400-14-2P

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

768400-16-4P 768400-18-6P 768400-21-1P

768400-26-6P 768400-29-9P 768400-32-4P

768400-35-7P 768400-37-9P 768400-40-4P

768400-43-7P 768400-46-0P


RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of prostaglandin analogs as EP4 receptor agonists for the treatment of glaucoma)

RN 768399-99-1 CAPLUS

CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]dihydro-2-oxo-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 768400-11-9 CAPLUS

CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]dihydro-2-oxo-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 768400-14-2 CAPLUS

CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(3R)-4,4-difluoro-3-hydroxy-4-phenylbutyl]dihydro-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 768400-16-4 CAPLUS

CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, dihydro-4-[(3R)-3-hydroxy-4-phenylbutyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 768400-18-6 CAPLUS

CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]dihydro-2-oxo-, 1-methylethyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 768400-21-1 CAPLUS

CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]tetrahydro-3-[6-(1H-tetrazol-5-yl)hexyl]-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 768400-26-6 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[3-[(4R)-dihydro-4-[(1E,3S)-3-hydroxy-4-phenyl-1-butenyl]-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 768400-29-9 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[3-[(4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 768400-32-4 CAPLUS  
CN 2H-1,3-Oxazin-2-one, 4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]tetrahydro-3-[3-[5-[1H-tetrazol-5-yl]-2-thienyl]propyl]-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 768400-35-7 CAPLUS  
CN 2H-1,3-Oxazin-2-one, 4-[(3R)-4,4-difluoro-3-hydroxy-4-phenylbutyl]tetrahydro-3-[3-[5-[1H-tetrazol-5-yl]-2-thienyl]propyl]-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 768400-37-9 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[3-[(4R)-dihydro-4-[(1E,3S)-3-hydroxy-4-phenyl-1-butenyl]-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 768400-40-4 CAPLUS  
CN 2-Thiophenecarboxylic acid, 5-[3-[(4R)-dihydro-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 768400-43-7 CAPLUS  
CN 5-Heptenoic acid, 7-[(4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]-, (5E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 768400-46-0 CAPLUS  
CN 5-Heptenoic acid, 7-[(4S)-4-[(3R)-4,4-difluoro-3-hydroxy-4-phenylbutyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]-, (5E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



IT 768400-09-5P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of prostaglandin analogs as EP4 receptor agonists for the treatment of glaucoma)  
RN 768400-09-5 CAPLUS  
CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(1E)-4,4-difluoro-3-oxo-4-phenyl-1-butenyl]dihydro-2-oxo-, 1-methylethyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN


ACCESSION NUMBER: 1990:459177 CAPLUS  
 DOCUMENT NUMBER: 113:59177  
 TITLE: Preparation of oxazolidinone penetration enhancing compounds  
 INVENTOR(S): Rajadhyaksha, Vithal J.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: PCT Int. Appl., 60 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9000407	A1	19900125	WO 1989-US2779	19890623
W: JP				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
US 4960771	A	19901002	US 1988-218316	19880712
EP 378657	A1	19900725	EP 1989-908033	19890623
EP 378657	B1	19940202		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 03500298	T2	19910124	JP 1989-507546	19890623
JP 2901297	B2	19990607		
AT 101046	E	19940215	AT 1989-908033	19890623
PRIORITY APPLN. INFO.:			US 1988-218316	A 19880712
			EP 1989-908033	A 19890623
			WO 1989-US2779	W 19890623
OTHER SOURCE(S):		CASREACT 113:59177; MARPAT 113:59177		
GI				




AB Title compds. I (R = H, C1-18 alkyl, cycloalkyl, aryl, aralkyl, alkoxy, etc.; X = O, R1N, R1 = H, alkyl, aralkyl, C1-18 acyl, cycloalkyl, etc.; Y = O, R2N, R2 = H, alkyl, aralkyl, cycloalkyl, C1-18 acyl, hydroxyalkyl, etc.; m = 2-4; n = 0-4, with several provisos) are prepared  
 Me(CH2)9CHNH2CH2OH and ethylene carbonate were heated to .apprx.110° to give 4-decyloxazolidin-2-one (II). In a test using isosorbide dinitrate (0.07%) and 1.4% II, II showed superior permeation enhancing properties compared to control and a known permeation enhancer.  
 IT 128276-14-2 128276-15-3  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (penetration enhancer for topical pharmaceuticals)  
 RW 128276-14-2 CAPLUS  
 CN 2H-1,3-Oxazin-2-one, 4-dodecyltetrahydro-3-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 128276-15-3 CAPLUS  
 CN 2H-1,3-Oxazin-2-one, 3-acetyl-4-dodecyltetrahydro- (9CI) (CA INDEX NAME)



PALM INTRANET

KM Day : Wednesday

Date: 9/7/2005

Time: 12:46:48

# Inventor Information for 10/797257

Inventor Name	City	State/Country
BILLOT, XAVIER	MONTREAL	CANADA
COLUCCI, JOHN	KIRKLAND	CANADA
HAN, YONGXIN	KIRKLAND	CANADA
WILSON, MARIE-CLAIRE	CARLSBAD SPRINGS	CANADA
YOUNG, ROBERT N.	SENNEVILLE	CANADA

Appln Info

Contents

Petition Info

Atty/Agent Info

Continuity Data

Foreign Data

Search Another: Application#  Searchor Patent#  SearchPCT /  /  Searchor PG PUBS #  SearchAttorney Docket #  SearchBar Code #  Search

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	606	544/96, 544/97, 514/228.8	USPAT	OR	OFF	2005/09/07 13:14